seen in 1% to 10% of KTx recipients and ultimately causes allograft failure, unless immunosuppression is tapered. [5] [6] [7] Recently we found BKPyV-specific immunoglobulin G (IgG) levels, especially determined in donors before KTx, to be strongly predictive of BKPyV viremia and BKPyVAN in recipients after KTx. 5 BKPyV is a member of the Polyomaviridae, which among others contains 13 species detected in humans, 8 including human polyomavirus 9 (HPyV9) and trichodysplasia spinulosa polyomavirus (TSPyV). TSPyV primary infection causes trichodysplasia spinulosa in immunocompromised patients, in whom it can be found in large quantities in affected skin and blood, but also in kidney tissue and urine. [9] [10] [11] [12] [13] TSPyV seroprevalence in healthy populations is high, approximately 75%, 1, 14 which suggests that asymptomatic persistent TSPyV infection is common.
HPyV9 was discovered in serum of a KTx patient. 15 A role for HPyV9 in hemorrhagic cystitis, bladder cancer, cutaneous T-cell lymphoma, and cutaneous squamous cell carcinoma has been explored, but thus far no pathogenic effect of HPyV9 has been found. Seroprevalence for this virus is lower than most other HPyVs (~20%). 1, 14, 16 We have previously observed an association between the HPyV9
and BKPyV infection in a small cohort of, mostly cadaveric, kidney (-pancreas) transplant patients (n = 99). Approximately 20% of these patients became HPyV9 viremic after KTx, which preferentially occurred among BKPyV viremic recipients (P < 0.05), especially in those with high BKPyV DNA loads (>10 3 copies/mL). 17 An association with Cytomegalovirus (CMV) viremia was not found, suggesting that the association between the HPyV9 and BKPyV was not merely the result of increased immunosuppression, but rather of a common risk factor shared between these polyomaviruses.
Since the detection of HPyV9 was associated with higher BKPyV loads, we wondered if HPyV9 somehow promotes BKPyV infection and could be involved in BKPyVAN development in KTx patients. In this study, we tested this hypothesis, although we are not aware of any documented complementarity/synergy between polyomaviruses, as for instance has been described between DNA viruses, such as hepatitis B and D virus. 18 At the same time, this approach offered the possibility to confirm our previously reported HPyV9 viremia rates in KTx patients, which were not found in a number of other comparable studies. 15, 19 Since TSPyV belongs to the same genus as HPyV9 (alpha polyomavirus), and is also detected in kidney tissue and urine, we included this polyomavirus in the analysis as well. 3.3 | DNA detection of BKPyV, TSPyV, and HPyV9
| OBJECTIVE
BKPyV, HPyV9, and TSPyV viremia was determined in serum and plasma with quantitative real-time PCR, as described. 4 | RESULTS
| Incidence of BKPyV viremia and BKPyVAN
In total, 209 KTx recipients were evaluated with regard to the incidence of BKPyV viremia and BKPyVAN within the first year after VAN RIJN ET AL.
| 1143
KTx. Fifty-three recipients (25%) became BKPyV viremic, and four of them developed BKPyVAN (Table 1 ).
| HPyV9 and TSPyV seropositivity and viremia among KTx donors and recipients
To investigate a possible effect on BKPyV infection and development of BKPyV viremia and BKPyVAN by coinfection with HPyV9 and TSPyV, pre-KTx seropositivity for HPyV9 and TSPyV were determined in both donors and recipients. Forty-five donors (22%) and 33 recipients (16%) were seropositive for HPyV9, and 184 donors (88%) and 186 recipients (89%) for TSPyV (Figure 1 ). HPyV9 and TSPyV seropositivity were distributed equally over age and sex of recipients ( relation between donor and recipient (sibling, parent, other families, partner, friends, or strangers), no trend towards a relationship with increased risk of HPyV9 infection was found (data not shown).
When we compared the incidence of BKPyV viremia and BKPyVAN in HPyV9 and TSPyV seropositive recipients, we did not observe specific associations to suggest that the BKPyV infection was related to previous or coincident HPyV9 or TSPyV infection. Only the MFI values for HPyV9
were significantly higher in BKPyV viremic recipients that developed BKPyVAN (P = 0.007). However, because this concerned only four recipients developing nephropathy, we are reluctant to conclude anything from this observation.
Previously we reported 21% HPyV9 DNA-positive KTx recipients in a cohort of kidney-pancreas transplant patients with deceased 26 who reported a prevalence of 27% in the KTx patients. 27 We assume that different immunosuppressive regimens or geographical differences explain the discrepancy in the prevalence of TSPyV infection in the primarily Dutch and Argentinian cohorts.
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